Loading Events

LifeSci Partners: Addressing the risks and challenges of a stock price heading towards $1.00. Now What?

DATE: March 28, 2022
TIME: 11:00 AM EDT

About The Event

Join us for an expert panel discussion of strategies for companies facing the dreaded $1 delisting threshold. We have gathered an experienced group of Wall Street veterans to cover every aspect a company needs to consider, including:

Company Strategies: How to avoid delisting? Navigating conversations with Nasdaq after receiving a warning letter. Rules, Timelines and Resolution

Legal Strategies: What actions do I need to take now? What is the timing? What are the notification and extension requirements?

Banking and Capital Markets Advice: Impact of a declining stock price on investor sentiment? Possible strategies for life on the OTCB. Alternatives for regaining listing and how to raise money at these prices?

No stone is left unturned in this discussion. We encourage everyone to listen in and learn more.


Andrew Hall, Managing Director, New Listing– NASDAQ
Andy has been with Nasdaq since 2004, and has held varies positions in the areas of relationship management and market intelligence. Since 2007, Andy has been on the New Listings team and has handled companies going public through a traditional private to public IPO. Andy’s focus is working with companies that are already public considering a Nasdaq listing which includes: NYSE transfers, NYSE American & OTC upgrades, and dual listings from a Canadian exchanges.
David A. Donohoe, Jr., Donohoe Advisory Associates LLC
David A. Donohoe Jr., is President of Donohoe Advisory, which provides consulting and advisory services to public companies and law firms with an emphasis on stock exchange listing matters. Since its formation in 2004, Donohoe Advisory has represented over 1,500 public companies in stock exchange listing matters, including uplistings from the OTC market, IPOs, reverse merger transactions with listed companies, and delisting hearings. In addition, Donohoe Advisory has assisted hundreds of issuers in structuring financing and acquisition transactions. Donohoe Advisory successfully completed 73 listings on Nasdaq and the NYSE in 2021. Since 2007, Mr. Donohoe has also served as a Managing Director in the Investment Banking Group for ROTH Capital Partners, LLC, a FINRA member firm, where he assists issuers in equity and debt financings. Prior to the formation of Donohoe Advisory in 2004, Mr. Donohoe served as Chief Counsel for the Listing Qualifications Department of The Nasdaq Stock Market where, among other things, he was responsible for the Nasdaq listing hearing process and for developing and implementing listing standards and related policies. Mr. Donohoe was employed by The Nasdaq Stock Market from 1995 through 2004. He received a B.A. in Economics from The University of Texas, Austin (1985) and a J.D. from the Catholic University of America (1988).
Hany Awadalla, Managing Director, Head of Investment Banking– LifeSci Capital
Mr. Awadalla has advised healthcare and life sciences companies on corporate finance and mergers and acquisitions for the past 35 years. He began his career focused on Mergers and Acquisitions at Merrill Lynch and then UBS. He was the Head of Healthcare Mergers and Acquisitions at Robertson Stephens and Wells Fargo. He was Head of Healthcare Investment Banking at Unterberg Towbin, a technology and healthcare boutique, which was acquired by what is now Canaccord. He has advised on over $20 billion of financing and M&A transactions in the healthcare sector. He received his MBA in Finance and MA in International Studies from the Wharton School and the University of Pennsylvania, respectively where he was a Lauder Fellow and his BA from Columbia University in East Asian Studies and Economics.